Janjigian Yelena Y, Braghiroli Maria Ignez
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 300 East 66th Street, Room 1033, New York, NY 10065, USA.
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Room 1033, New York, NY 10065, USA.
Surg Oncol Clin N Am. 2017 Apr;26(2):313-324. doi: 10.1016/j.soc.2016.10.005. Epub 2017 Feb 10.
Esophagogastric cancer is a worldwide health problem. The addition of the epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab to chemotherapy increased the overall survival of patients with metastatic HER2-positive esophagogastric cancer. This article discusses the available data to support HER2 as validated biomarker and recently completed and ongoing clinical trials of HER2-directed agents in metastatic and localized disease. Also reviewed is the mechanisms of resistance for HER2-directed therapy and ongoing research strategies including new imaging techniques and studies with patient-derived xenografts.
食管癌是一个全球性的健康问题。在化疗中添加表皮生长因子受体2（HER2）导向抗体曲妥珠单抗可提高转移性HER2阳性食管癌患者的总生存率。本文讨论了支持HER2作为有效生物标志物的现有数据，以及最近完成和正在进行的HER2导向药物在转移性和局限性疾病中的临床试验。还回顾了HER2导向治疗的耐药机制以及正在进行的研究策略，包括新的成像技术和患者来源异种移植研究。
